Becton, Dickinson and Company (BDX) Shares Bought by Marshall Wace LLP

Marshall Wace LLP lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 974.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,879 shares of the medical instruments supplier’s stock after acquiring an additional 18,935 shares during the period. Marshall Wace LLP’s holdings in Becton, Dickinson and were worth $4,071,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in BDX. Almanack Investment Partners LLC. acquired a new stake in shares of Becton, Dickinson and in the first quarter worth $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% during the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 60 shares in the last quarter. Financial Architects Inc boosted its stake in Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after buying an additional 54 shares in the last quarter. Finally, Guardian Life Insurance Co. of America boosted its stake in Becton, Dickinson and by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 6 shares in the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Shares Bought by Marshall Wace LLP” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/20/becton-dickinson-and-company-bdx-shares-bought-by-marshall-wace-llp.html.

A number of equities research analysts have weighed in on BDX shares. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Bank of America Corporation reiterated a “buy” rating and set a $225.00 price target (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday, July 17th. Finally, BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $196.93.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company (NYSE BDX) opened at 193.00 on Wednesday. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The company has a market capitalization of $43.92 billion, a PE ratio of 55.89 and a beta of 1.06. The firm’s 50 day moving average price is $199.01 and its 200-day moving average price is $191.58.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.35 EPS. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply